Literature DB >> 24833875

Cirrhosis and its complications: evidence based treatment.

Salman Nusrat1, Muhammad S Khan1, Javid Fazili1, Mohammad F Madhoun1.   

Abstract

Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver disease. It is among the ten leading causes of death in United States. Cirrhosis can result in portal hypertension and/or hepatic dysfunction. Both of these either alone or in combination can lead to many complications, including ascites, varices, hepatic encephalopathy, hepatocellular carcinoma, hepatopulmonary syndrome, and coagulation disorders. Cirrhosis and its complications not only impair quality of life but also decrease survival. Managing patients with cirrhosis can be a challenge and requires an organized and systematic approach. Increasing physicians' knowledge about prevention and treatment of these potential complications is important to improve patient outcomes. A literature search of the published data was performed to provide a comprehensive review regarding the management of cirrhosis and its complications.

Entities:  

Keywords:  Ascites; Hepatic encephalopathy; Hepatopulmonary syndrome; Portal hypertension; Portopulmonary hypertension; Varices

Mesh:

Year:  2014        PMID: 24833875      PMCID: PMC4017060          DOI: 10.3748/wjg.v20.i18.5442

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  228 in total

1.  Surrogate endpoints and non-inferiority trials in chronic viral hepatitis.

Authors:  Ivan Gentile; Guglielmo Borgia
Journal:  J Hepatol       Date:  2010-02-18       Impact factor: 25.083

Review 2.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

3.  Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.

Authors:  Lucio Amitrano; Maria Anna Guardascione; Antonella Menchise; Rossana Martino; Mariano Scaglione; Sabrina Giovine; Luigia Romano; Antonio Balzano
Journal:  J Clin Gastroenterol       Date:  2010-07       Impact factor: 3.062

4.  Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies.

Authors:  J W Conn; D L Hinerman
Journal:  Metabolism       Date:  1977-12       Impact factor: 8.694

5.  Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.

Authors:  K M Peltekian; F Wong; P P Liu; A G Logan; M Sherman; L M Blendis
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

6.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

Authors:  B Bernard; J D Grangé; E N Khac; X Amiot; P Opolon; T Poynard
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

7.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

8.  A randomized controlled trial of acarbose in hepatic encephalopathy.

Authors:  Sandro Gentile; Giuseppina Guarino; Marco Romano; Ivo A Alagia; Maura Fierro; Stefano Annunziata; Paolo L Magliano; Antonietta G Gravina; Roberto Torella
Journal:  Clin Gastroenterol Hepatol       Date:  2005-02       Impact factor: 11.382

9.  Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators.

Authors:  Gennaro D'Amico; Roberto De Franchis
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

10.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

View more
  52 in total

1.  Changing common sense: Anti-platelet/coagulation therapy against cirrhosis.

Authors:  Yoshihiro Ikura; Tatsuya Osuga
Journal:  World J Hepatol       Date:  2015-07-08

2.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 3.  Considerations for bariatric surgery in patients with cirrhosis.

Authors:  George Boon-Bee Goh; Philip R Schauer; Arthur J McCullough
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

4.  Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.

Authors:  Tsai-Ling Liu; Justin Trogdon; Morris Weinberger; Bruce Fried; A Sidney Barritt
Journal:  Dig Dis Sci       Date:  2016-08-01       Impact factor: 3.199

5.  The growing burden of liver cirrhosis: implications for preventive measures.

Authors:  Martin C S Wong; Junjie Huang
Journal:  Hepatol Int       Date:  2018-04-20       Impact factor: 6.047

6.  Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.

Authors:  Nicholas G Theodorakis; Yining N Wang; Vyacheslav A Korshunov; Mary A Maluccio; Nicholas J Skill
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

7.  A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.

Authors:  Biyao Zou; Yee Hui Yeo; Donghak Jeong; Haesuk Park; Edward Sheen; Dong Hyun Lee; Linda Henry; Gabriel Garcia; Erik Ingelsson; Ramsey Cheung; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2019-10-09       Impact factor: 3.199

Review 8.  Outcomes of abdominal surgery in patients with liver cirrhosis.

Authors:  Juan C Lopez-Delgado; Josep Ballus; Francisco Esteve; Nelson L Betancur-Zambrano; Vicente Corral-Velez; Rafael Mañez; Antoni J Betbese; Joan A Roncal; Casimiro Javierre
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 9.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

10.  Bariatric Surgery in Cirrhotic Patients: a Matched Case-Control Study.

Authors:  Nicolás Quezada; Gregorio Maturana; María Jesús Irarrázaval; Rodrigo Muñoz; Sebastián Morales; Pablo Achurra; Cristóbal Azócar; Fernando Crovari
Journal:  Obes Surg       Date:  2020-08-17       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.